MA47141A - Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation - Google Patents

Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation

Info

Publication number
MA47141A
MA47141A MA047141A MA47141A MA47141A MA 47141 A MA47141 A MA 47141A MA 047141 A MA047141 A MA 047141A MA 47141 A MA47141 A MA 47141A MA 47141 A MA47141 A MA 47141A
Authority
MA
Morocco
Prior art keywords
oxo
dgla
epa
preparation
compositions consisting
Prior art date
Application number
MA047141A
Other languages
English (en)
Inventor
John Climax
David Coughlan
Mehar Manku
Original Assignee
Ds Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ds Biopharma Ltd filed Critical Ds Biopharma Ltd
Publication of MA47141A publication Critical patent/MA47141A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
MA047141A 2015-05-13 2016-05-12 Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation MA47141A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160863P 2015-05-13 2015-05-13

Publications (1)

Publication Number Publication Date
MA47141A true MA47141A (fr) 2019-11-06

Family

ID=56131573

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047141A MA47141A (fr) 2015-05-13 2016-05-12 Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation

Country Status (7)

Country Link
US (4) US10047033B2 (fr)
EP (1) EP3294282A1 (fr)
JP (3) JP2018524274A (fr)
CN (3) CN117402059A (fr)
HK (1) HK1250345A1 (fr)
MA (1) MA47141A (fr)
WO (1) WO2016181221A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692986A1 (fr) 2014-06-04 2020-08-12 DS Biopharma Limited Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
JP2018524274A (ja) * 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
US9855238B2 (en) * 2015-12-18 2018-01-02 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
JP2022505215A (ja) * 2018-10-18 2022-01-14 ディーエス バイオファーマ リミテッド 炎症性、線維性、および増殖性状態を治療するためのｄｇｌａおよび／または１５－ｈｅｔｒｅ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352700A (en) 1988-01-14 1994-10-04 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
NZ709083A (en) 2012-12-24 2020-07-31 Qualitas Health Inc Eicosapentaenoic acid (epa) formulations
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014142364A2 (fr) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions et méthodes de traitement de la stéatohépatite non alcoolique
JP2018524274A (ja) * 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法

Also Published As

Publication number Publication date
JP2021075563A (ja) 2021-05-20
JP7229285B2 (ja) 2023-02-27
WO2016181221A1 (fr) 2016-11-17
US20210230094A1 (en) 2021-07-29
US20180201566A1 (en) 2018-07-19
WO2016181221A9 (fr) 2017-05-04
JP2018524274A (ja) 2018-08-30
EP3294282A1 (fr) 2018-03-21
JP2023065454A (ja) 2023-05-12
CN117402059A (zh) 2024-01-16
US20220324788A1 (en) 2022-10-13
US20160362358A1 (en) 2016-12-15
CN107847477A (zh) 2018-03-27
US10047033B2 (en) 2018-08-14
CN113896628A (zh) 2022-01-07
US10570083B2 (en) 2020-02-25
HK1250345A1 (zh) 2018-12-14

Similar Documents

Publication Publication Date Title
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA41020A (fr) Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA47522A (fr) Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
MA44081A (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation